Health Canada

1161 articles with Health Canada

• Health Canada announces members of the new Science Advisory Committee on Pest Control Products

  6/27/2022

  The Government of Canada takes pesticide safety very seriously, and it is working to ensure an open and inclusive process in the areas of safety, transparency and sustainability.

• Advisory - Health Canada seizes unauthorized skin lightening and sex enhancement products in Lethbridge and Calgary, AB, because they may pose serious health risks

  6/16/2022

  Health Canada maintains a list of unauthorized health products that may pose serious health risks so that Canadians can easily identify those they may have purchased and take appropriate action.

• Johnson & Johnson Vision on Track for Multinational Launch of New Contact Lens Innovation: ACUVUE® OASYS MAX 1-Day

  6/15/2022

  Johnson & Johnson Vision announced it has received U.S. Food & Drug Administration clearance, Health Canada approval and completed CE Mark activities for its latest contact lens innovation, ACUVUE® OASYS MAX 1-Day and ACUVUE® OASYS MAX 1-Day MULTIFOCAL.

• Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS

  6/13/2022

  Health Canada decision signifies the first global regulatory approval for Amylyx and the first new therapy for ALS approved in Canada since 2018.

• Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

  6/8/2022

  Medison Pharma is pleased to announce the approval of KIMMTRAK® by Health Canada and Therapeutics Goods Administration for the treatment of unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma that affects the eye.

• Health Canada approves (Pr)Tabrecta®: Targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations

  6/8/2022

  Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has granted a Notice of Compliance with conditions for Tabrecta® for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer harbouring mesenchymal-epithelial transition exon 14 skipping alterations.

• Health Canada authorizes VABYSMO® (faricimab injection) for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)

  6/1/2022

  Hoffmann-La Roche Limited is pleased to announce that Health Canada authorized VABYSMO® for the treatment of neovascular age-related macular degeneration and diabetic macular edema, two of the leading causes of vision loss among Canadians.

• AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALS

  5/26/2022

  AB Science SA announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis, meaning that the information and materials submitted by AB Science has been screened and found acceptable for review as a New Drug Submission.

• Teleflex Announces Health Canada Approval of MANTA® Vascular Closure Device

  5/18/2022

  Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced that it received Health Canada approval for the MANTA ® Vascular Closure Device.

• Health Canada Accepts Snds Filing and Grants Priority Review for Oral Edaravone Formulation for the Treatment of ALS

  5/13/2022

  Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that Health Canada has accepted the filing of a Supplement to a New Drug Submission for an investigational oral formulation of edaravone indicated for the treatment of amyotrophic lateral sclerosis.

• Government of Canada Invests $2 million for research on innovative organ and tissue donation projects

  4/29/2022

  To close out National Organ Transplantation and Donation Awareness Week, the Honourable Jean-Yves Duclos, Minister of Health, announced funding for two new projects through Innovative Solutions Canada that will focus on cutting-edge research in the area of organ and tissue donation in the hopes of improving those statistics.

• Health Canada Approves 3rd Generation Clarius Wireless Ultrasound Scanners that Connect with Apple and Android Devices

  4/21/2022

  Health Canada Approves 3rd Generation Clarius Wireless Ultrasound Scanners that Connect with Apple and Android Devices.

• Health Canada Approves KEYTRUDA® (pembrolizumab) for the treatment of adult patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery

  4/18/2022

  Merck announced that Health Canada has granted approval for KEYTRUDA®, Merck's anti-PD-1 therapy, as a treatment for adult patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery.

• Health Canada Approves GARDASIL (Human Papillomavirus 9-valent Vaccine, Recombinant) for the Prevention of Oropharyngeal and Other Head and Neck Cancers

  4/11/2022

  Merck  announced today that Health Canada has approved an expanded indication of

• bioLytical Laboratories Inc. Receives Health Canada Authorization for the iStatis COVID-19 Antigen Home Test

  4/2/2022

  bioLytical Laboratories Inc. announced that it is launching a second test on its new platform, iStatis, after receiving Health Canada authorization for the iStatis COVID-19 Antigen Home Test for its immediate market entry into Canada.

• Health Canada authorizes Héma-Québec submission to make source plasma donor screening criteria more inclusive for men who have sex with men

  3/24/2022

  Health Canada authorized a submission from Héma-Québec to change their source plasma donor screening criteria.

• Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain

  3/17/2022

  Heron Therapeutics, Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) to commercialize ZYNRELEF (bupivacaine and meloxicam extended-release solution) for instillation into the surgical wound for postoperative analgesia after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty surgical procedures.

• The Government of Canada announces additional funding to four safer supply pilot projects

  3/17/2022

  The evidence is clear that the COVID-19 pandemic has contributed to a worsening of the overdose crisis, which continues to affect individuals, families and communities across Canada every single day.

• Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)

  3/17/2022

  Moderna, Inc. announced that Health Canada has approved the use of Moderna's mRNA COVID-19 vaccine, SPIKEVAX™, in a two-dose series of 50 µg per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 to11 years.

• PepGen Announces Approval by Health Canada of CTA to Begin First in Human Trials of PGN-EDO51 to Treat Duchenne Muscular Dystrophy

  3/15/2022

  PepGen Inc. announced approval by Health Canada of PepGen’s Clinical Trial Application authorizing initiation of first-in-human trials of PepGen’s lead Enhanced Delivery Oligonucleotide candidate, PGN-EDO51.